Vaso AI Stock Analysis
Want to see VASO full AI Analyst Report?
Vaso (VASO) AI Stock Analysis
Vaso
(Other OTC:VASO)
The overall score of 62 reflects a company with a solid financial foundation but significant operational challenges. The primary positive driver is strong bullish momentum in the stock price, supported by a robust, debt-free balance sheet. These strengths are counterbalanced by the primary risk: a clear downward trend in revenue and profitability that has led to volatile cash flows. The reasonable P/E valuation provides some support but is contingent on a turnaround that is not yet evident in the financial statements.
Vaso (VASO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $47.58M
- Dividend Yield
- ―
- Average Volume (3M)
- 125.30K
- Price to Earnings (P/E)
- 16.7
- Beta (1Y)
- 0.56
- Revenue Growth
- -23.30%
- EPS Growth
- -140.14%
- Country
- US
- Employees
- 282
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Vaso Business Overview & Revenue Model
Company Description
Vaso Corporation is a diversified enterprise engaged in both the healthcare equipment and information technology industries, serving markets within the United States and globally. The company's operations are structured across three primary divisions...
Vaso Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with minimal debt and growing equity (Score 75). However, the income statement shows declining revenue and severe margin compression (Score 35), and cash flow is volatile with a recent dramatic decline (Score 40). The overall profile is of a well-capitalized company facing significant operational headwinds.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
40Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.22M | 89.10M | 86.77M | 81.02M | 80.02M | 75.58M |
| Gross Profit | 51.98M | 54.67M | 52.05M | 50.59M | 48.48M | 43.13M |
| EBITDA | 413.00K | -423.00K | 2.10M | 5.95M | 8.38M | 6.66M |
| Net Income | 2.79M | 1.57M | 951.00K | 4.80M | 11.87M | 6.10M |
Balance Sheet | ||||||
| Total Assets | 85.91M | 88.35M | 82.94M | 75.76M | 72.66M | 52.36M |
| Cash, Cash Equivalents and Short-Term Investments | 38.29M | 35.05M | 26.27M | 25.32M | 20.32M | 6.65M |
| Total Debt | 1.79M | 1.81M | 2.38M | 2.06M | 1.80M | 1.39M |
| Total Liabilities | 56.70M | 58.92M | 55.24M | 48.91M | 49.78M | 41.05M |
| Stockholders Equity | 29.21M | 29.43M | 27.70M | 26.84M | 22.88M | 11.31M |
Cash Flow | ||||||
| Free Cash Flow | 6.90M | 8.35M | 1.83M | 4.57M | 13.85M | 7.40M |
| Operating Cash Flow | 7.86M | 9.27M | 3.28M | 5.30M | 14.42M | 7.82M |
| Investing Cash Flow | -821.00K | -725.00K | 11.73M | -5.66M | -8.42M | -260.00K |
| Financing Cash Flow | -834.00K | 248.00K | -89.00K | -134.00K | -230.00K | -8.33M |
Vaso Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.29, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 39.09 is Neutral, neither overbought nor oversold. The STOCH value of 37.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VASO.
Vaso Risk Analysis
Vaso disclosed 32 risk factors in its most recent earnings report. Vaso reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksVaso Peers Comparison
Overall Rating
VASO62Neutral
BEAT43Neutral
VSEE40Underperform
HCTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | $47.58M | 16.67 | 5.59% | ― | -23.30% | -140.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $21.55M | -0.81 | -402.72% | ― | ― | 38.22% | |
| 40Underperform | $175.37K | -0.01 | -400.87% | ― | -30.28% | 38.11% | |
| 38Underperform | $2.89M | -0.00 | -43.51% | ― | 141.89% | 99.35% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VASO | Vaso Corp | 0.27 | 0.13 | 92.86% | |
| HCTI | Healthcare Triangle, Inc. | 3.16 | -2156.84 | -99.85% | |
| BEAT | Heartbeam, Inc. | 0.34 | -1.34 | -79.76% | |
| VSEE | Vsee Health, Inc. | 0.20 | -51.80 | -99.62% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.42 | -0.45 | -51.72% | |
| MGRX | Mangoceuticals, Inc. | 0.15 | -0.99 | -87.19% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026
